transcodetherapeutics.com (RNAZ) Amount of Cash per Share

Corporate emblem and logo of TransCode (RNAZ)

TransCode Therapeutics (RNAZ) develops RNA-based drugs to combat brain and breast tumors using a unique molecule delivery system. Cash per share demonstrates asset liquidity, where 0.27 represents the current metric. Processes are accelerating through the implementation of robotic bio-screening. Simultaneously, the company is adopting green chemistry principles for the safe disposal of reagents and energy efficiency.

TransCode (RNAZ): Cash Funds per Share from 07/04/2022 to 11/20/2026

Analytical breakdowns for TransCode (RNAZ)

- market price and analyst price targets:
- cash position and cash flow details:
General company analysis:TransCode Therapeutics, Inc., RNAZ
Original product of TransCode Therapeutics Inc.

Cash per share determines the volume of free liquidity attributable to a single security. The dynamics of liquid assets per share allow for the real-time tracking of a company's actual cash reserves. This metric is calculated by dividing the total cash balance by the number of outstanding shares. For TransCode Therapeutics (RNAZ), this resource is critical for financing clinical trials of RNA therapies. Sufficient cash ensures the autonomy of cancer drug development and resilience against market volatility.

Key competitors

TEM (Tempus AI Inc) - Cash Calculated per Single Share|Cash per Share QGEN|IONS - Cash on Hand per Share|Cash Funds per Share Repligen RGEN|RNA: Cash Funds per Single Share|CRSP: Cash per Single Share|GeneDx Corp (WGS) - Cash per Single Share|RARE: Cash per Share|BEAM - Cash Funds Calculated per Share|SRPT (Sarepta Therapeutics) - Cash per Share|Cash per Single Share Twist Bioscience Inc (TWST)|Cash per Share TXG|Cash Funds Calculated per Share Intellia|Stoke - Cash per Single Share|BLFS: Cash Funds per Single Share|Wave Life Sciences Corp - Cash per Share|Maze Therapeutics, Inc. (MAZE) - Cash per Single Share|Sionna Therapeutics Inc (SION) - Cash Funds per Share|Cash per Single Share Prime Medicine Corp|Cash Funds per Share tayshagtx.com|QURE - Cash Funds Volume per Share|Cash per Single Share MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Cash Funds Volume per Share|Cash per Share SLDB (Solid Biosciences Inc.)|Amount of Cash per Share OCGN|PacBio Corp - Cash per Share|Benitec Biopharma Inc. (BNTC) - Cash per Single Share|DSGN: Cash per Share|Cash Funds per Single Share RCKT|Cash per Single Share FDMT|Cash Funds per Single Share LXEO (Lexeo Therapeutics)|Cash per Share KRRO|Editas Medicine, Inc. - Cash Funds per Single Share|Cash Funds per Share Silence Therapeutics Inc. SLN|Cash per Share ProQR Therapeutics N.V. PRQR|CDXS: Cash per Single Share|Cash Funds Volume per Share Sangamo (SGMO)|NAUT (Nautilus Bio) - Cash per Single Share|MGX - Cash Funds Calculated per Share|DTIL (Precision BioSciences Inc.) - Cash per Share|generationbio.com (GBIO) - Cash Funds Calculated per Share|Cash Funds per Share Boundless Bio Inc (BOLD)|Cash per Share Exicure Inc. (XCUR)|Cash Funds per Share imunon.com IMNN|Cash per Share Phio Pharmaceuticals PHIO|Mustang Bio Inc - Cash per Share|Amount of Cash per Share BNGO (bionanogenomics.com)|Applied DNA Sciences (APDN) - Cash Funds per Share|Bluebird Bio - Amount of Cash per Share|IPA (ImmunoPrecise Antibodies Ltd) - Cash per Share|Cash on Hand per Share Omega Therapeutics, Inc. OMGA|Cash per Share OMIC|RGLS (Regulus Therapeutics Inc.) - Amount of Cash per Share|Cash per Share SYRS (Syros Pharmaceuticals Inc.)|Cash Calculated per Single Share TBIO (Codex DNA)|TCON - Cash Funds per Share|Cash on Hand per Share Unity Biotechnology